The prevalence of PH was 12.8% in those hospitalized in 2018 with left heart disease, a lower percentage than found in previous research.

Mavacamten, a drug initially developed to treat hypertrophic cardiomyopathy, has shown signs of reducing heart stress in ...

Whether a drug that selectively targets fat mass, with modest weight loss, translates into CV benefits awaits further study.

Cardiovascular disease, sometimes abbreviated as CVD, is the leading cause of death worldwide. It’s a catchall term for heart ...

USA: A recent study from the EMBARK-HFpEF trial has revealed promising results regarding using mavacamten, a cardiac myosin ...

STAT asked 11 experts, including the FDA commissioner, why the world's wealthiest nation is doing so poorly on cardiovascular ...

Postmarket data on MitraClip lend further support to the idea that this subgroup fares as well as the overall SMR population.

Among the benefits of semaglutide, the GLP-1 receptor agonist may protect against heart failure events in patients with type 2 diabetes and CKD.

The risk of heart disease increases with age for most people, however, for women that may be even more true. The menopause ...

Global Commercial Launch Preparations Underway for First Potential Approval Towards Building Specialty Cardiovascular Franchise Company Recently Launched Unbranded Disease Awareness Campaign “HCM ...

Oct. 4, 2024 — Researchers identified a lipid that is involved in regulating cardiac ion channels, providing insights into possible mechanisms of cardiac arrhythmias in heart failure and a ...